This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zelko, I.
Right arrow Articles by Negishi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zelko, I.
Right arrow Articles by Negishi, M.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, April 2001, p. 2838-2846, Vol. 21, No. 8
0270-7306/01/$04.00+0   DOI: 10.1128/MCB.21.8.2838-2846.2001

The Peptide Near the C Terminus Regulates Receptor CAR Nuclear Translocation Induced by Xenochemicals in Mouse Liver

Igor Zelko, Tatsuya Sueyoshi, Takeshi Kawamoto, Rick Moore, and Masahiko Negishi*

Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709

Received 20 October 2000/Returned for modification 3 January 2001/Accepted 16 January 2001


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

In response to phenobarbital (PB) and other PB-type inducers, the nuclear receptor CAR translocates to the mouse liver nucleus (T. Kawamoto et al., Mol. Cell. Biol. 19:6318-6322, 1999). To define the translocation mechanism, fluorescent protein-tagged human CAR (hCAR) was expressed in the mouse livers using the in situ DNA injection and gene delivery systems. As in the wild-type hCAR, the truncated receptor lacking the C-terminal 10 residues (i.e., AF2 domain) translocated to the nucleus, indicating that the PB-inducible translocation is AF2 independent. Deletion of the 30 C-terminal residues abolished the receptor translocation, and subsequent site-directed mutagenesis delineated the PB-inducible translocation activity of the receptor to the peptide L313GLL316AEL319. Ala mutations of Leu313, Leu316, or Leu319 abrogated the translocation of CAR in the livers, while those of Leu312 or Leu315 did not affect the nuclear translocation. The leucine-rich peptide dictates the nuclear translocation of hCAR in response to various PB-type inducers and appears to be conserved in the mouse and rat receptors.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

Organisms are capable of inducing numerous xenochemical- and steroid-metabolizing enzymes such as cytochromes P450 (CYPs) in liver microsomes, increasing metabolic capability against xenochemical toxicity and carcinogenicity. Phenobarbital (PB), the prototype of structurally diverse xenochemicals, induces pleiotropically hepatic genes in mammalian species from mouse to human, with the CYP2B genes being most dramatically upregulated. A conserved 51-bp PB-responsive enhancer module (PBREM) has recently been located in the mouse, rat, and human CYP2B genes (9, 21). PB responsiveness of the region, including the 51-bp sequence, has been observed independently by various laboratories (16, 19, 20). Moreover, the nuclear receptor CAR (constitutive active receptor or constitutive androstane receptor) has been found to regulate the induction of the CYP2B genes, as well as the transactivation of PBREM (10, 21). CAR is retained in the cytoplasm of control hepatocytes and translocates to the nucleus following PB treatment (13). Nuclear translocation appears to be a general process through which CAR regulates the CYP2B induction, since various PB-type inducers (e.g., chloropromazine, chlorinated biphenyls, and methoxychlor) are also capable of translocating CAR into the nucleus in livers. The molecular and cellular mechanisms underlying the xenochemical-responsive nuclear translocation regulated by PB-type inducers remain a question of major interest.

The fluorescent protein-tagged hCAR, expressed in transformed cell lines such as HepG2 and HEK293, translocates spontaneously to the nucleus without exposing the cells to PB-type inducers (13). These in vitro systems provided a practical tool for the initial identification of signal sequences of CAR that regulate its nuclear translocation. To understand the molecular basis underlying CAR for nuclear translocation, we constructed various fluorescent protein-tagged CAR expression vectors and investigated the nucleocytoplasmic localization of these truncated or mutated CAR proteins expressed in HEK293 cells. Subsequently, these regulatory sequences were tested for their functions in livers using in situ injection of various CAR expression vectors. We herein describe experimental considerations that lead us to propose that the leucine-rich sequence near the C terminus regulates the xenochemical-induced nuclear translocation of CAR in mouse livers in vivo.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

Plasmids. Polymerase chain amplification was employed using pT7HisMyc-hCAR plasmid, Pfu DNA polymerase, and specific sets of primers to generate deletion mutants of CAR with newly created XhoI and EcoRI sites at the 5' and 3' ends, respectively. PCR amplification was done with primers that amplified the nucleotides encoding amino acids 1 to 348 (hCARwt), 1 to 338 (hCAR1-338), 1 to 328 (hCAR1-328), 1 to 318 (hCAR1-318), and 1 to 308 (hCAR1-308). Amplified fragments were digested with these two enzymes and inserted into pEGFP-C1, pECFP-C1, or pEYFP-C1 vectors (Clontech, Palo Alto, Calif.) to give an in-frame N-terminal fusion with one of the green (GFP), cyan (CFP), or yellowish (YFP) fluorescent proteins. A human glucocorticoid receptor (hGR)cDNA (provided by John Cidlowski) was also cloned into pEYFP-C1 or pECFP-C1 vector. Site-directed mutagenesis of hCAR and mouse CAR (mCAR) in pEYFP-C1 was conducted according to the instruction manual for the QuickChange site-directed mutagenesis system (Stratagene, La Jolla, Calif.). Nucleotides encoding leucines 312, 313, 315, 316, and 319 in hCAR and leucines 326 and 329 in mCAR, as well as Gly314 and Glu318 in hCAR, were mutated to encode alanines. All mutations and deletions were confirmed by sequencing, and plasmids bearing the CAR cDNAs with mutations or deletions were prepared using Qiagen Plasmid Maxi Kit (Qiagen, Valencia, Calif.). PBREM-tk-luciferase reporter gene was constructed in the pGL3 plasmid (21). A mouse SRC-1 cDNA, corresponding to amino acid residues from 633 to 1405, was amplified by using Pfu DNA polymerase and a specific set of primers having EcoRI and HindIII restriction sites at the 5' and 3' ends, respectively. Amplified cDNA was cloned into pcDNA3.1 Myc/His plasmid (Invitrogen) with the Kozak sequence at the 5' end. The SRC-1 cDNA was verified by sequencing.

DNA transfections and visualization of fluorescent protein-tagged CAR in HEK293 cells. Cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum and 100 U of penicillin per ml and 100 µg of streptomycin per ml at 37°C under a 5% CO2 atmosphere. For analysis of nuclear translocation, cells in an 8-well Lab-Tek Chamber Slide (Nalge Nunc, Naperville, Ill.) were switched to DMEM without phenol red, transfected with various plasmids using the calcium phosphate method (CellPhect Kit; Pharmacia), and cultured for an additional 24 h. Fluorescence-positive cells were identified with Axiovert 35 inverted fluorescence microscope (Zeiss) equipped with filters from Omega optics (Brattleboro, Vt.). YFP and GFP fluorescences were detected by using an XF104 filter, while CFP fluorescence was visualized by using an XF113 filter. Fluorescent images of liver cells were captured with Spot II cooled charge-coupled device camera (Diagnostic Instruments, Sterling Heights, Mich.) and processed using the accompanying software package. Nucleocytoplasmic localization of fluorescent protein-tagged CAR or GR was determined by counting cells. GFP fluorescence-positive cells were classified into three different categories: N<C for predominantly cytoplasmic fluorescence, N=C for equal fluorescence distribution in both the cytoplasmic and the nuclear regions, and N>C for preferentially nuclear fluorescence.

For analysis of SRC-1 coactivation HEK293 cells were transfected with pGL3-tk-mPBREM and pRL-CMV plasmids using calcium phosphate coprecipitation. The pcDNA3.1 Myc/His (Invitrogen) plasmid containing cDNA for wild-type hCAR and its mutant forms was cotransfected alone or with pcDNA3.1-mSRC-1 vector, and the luciferase activity was assayed 24 h after transfection. The promoter activities were determined from three independent transfections and normalized against Renila luciferase activities.

Expression of fluorescent protein-tagged CAR in livers. A portion of the liver was exposed through a ventral midline incision, and 80 µg of a given plasmid DNA in 300 µl of minimal essential medium was injected into three different spots, as previously described (21), or the expression plasmids (10 µg) were injected through the tail vein using TransIT In Vivo Gene Delivery System (Mirus, Madison, Wis.) according to the manufacturer's protocol. Then, two doses of xenochemicals were administered intraperitoneally at 2 and 5 h after the injection: chloropromazine (CPZ; 50 and 25 mg/kg, respectively), PB (100 mg/kg), or 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP; 0.33 mg/kg). The mice were sacrificed 3 h after the last treatment with xenochemical, and a block of the liver was frozen for preparing the sections (8-µm thickness) using Tissue-Tek OTC compound (Sakyra Finetek, Torrance, Calif.). One of every other four consecutive sections was placed on a cover glass (three sections per glass). Liver sections on cover glasses were fixed with 4% paraformaldehyde, washed once with phosphate-buffered saline, dehydrated in methanol, and stained for nuclei using 0.5 µg of Hoechst S-33258 per ml in 80% glycerol.

Gel shift assays. The TNT-Coupled Reticulocyte Lysate System (Promega) was used to prepare in vitro-translated CAR and RXRalpha as described in our previous study (21). These in vitro-translated receptors were incubated with 10 µl of HEPES buffer (pH 7.6) containing 0.5 mM dithiothreitol, 15% glycerol, 2 µg of poly(dI-dC), 0.05% NP-40, 50 mM NaCl, and approximately 30,000 cpm of 32P-end-labeled oligonucleotide.


    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

Nuclear localization of hCAR in HEK293 cells. The PBREM-tk-CAT reporter gene is activated by hCAR in cotransfected cells such as HepG2 and HEK293 in the absence of inducers such as PB and TCPOBOP (10). The activation appears to occur because hCAR is inherently active and always in the nucleus of the transfected cells (13). YFP-tagged hCAR was expressed in the nucleus of the transfected HEK293 cells, whereas CFP-tagged hGR was expressed in the cytoplasm and dexamethasone treatment translocated the GR into the nucleus (Fig. 1A).


View larger version (27K):
[in this window]
[in a new window]
  		FIG. 1.   Nucleocytoplasmic distribution of the wild-type and truncated CARs in HEK293 cells. (A) Both YFP-CAR and CFP-GR expression plasmids were cotransfected into HEK293 cells. After being cultured for 24 h, the transfected cells were treated with dexamethasone (+DEX, 0.1 µM) or dimethyl sulfoxide (-DEX) for 3 h and visualized under a fluorescence microscope. (B) Various truncated hCARs were constructed, expressed in HEK293 cells, and visualized under a fluorescent microscope as described in Materials and Methods. (C) Deletion mutants are shown underneath the wild-type (hCARwt) with numbers indicating deletions from the C-terminal end. The cells expressing hCAR were visualized and evaluated for the nucleocytoplasmic distribution of the receptor: N<C for cytoplasmic dominant fluorescence; N=C for equal fluorescence distribution in both cytoplasmic and nuclear regions; and N>C for nuclear dominant fluorescence.

Residues were successively deleted from the C terminus of hCAR, and the C-terminal truncated receptors were constructed into pEGFP-C1 vector and transfected into HEK293 cells (Fig. 1B and C). Even when the first 10 residues were removed, the receptor (hCAR1-338) still accumulated in the nucleus, suggesting that hCAR1-338 retained the translocation capability. However, deletion of the additional 10 residues decreased dramatically the nuclear translocation capability of the receptor. In fact, none of the cells displayed nuclear dominant localization of the hCAR1-328. The lack of the nuclear accumulation was not due to a stability of the deleted CAR protein since Western blot analysis of the cell extracts showed the expression of both hCARwt and hCAR1-328 with the expected sizes at similar levels in the transfected HEK293 cells (data not shown). In further deletion, hCAR1-318 behaved similarly to the hCAR1-328 with respect to the translocation capability. These results suggested that a regulatory information for the nuclear translocation might lie within the 20-amino-acid residue segment between positions 319 and 338 of the receptor. We then examined whether these residues regulated the nuclear translocation of CAR in mouse liver in vivo following treatment with PB or other PB-type inducers.

PB-responsive nuclear translocation in livers. Our previous immunochemical analyses of mCAR in mouse livers and primary hepatocytes have shown that mCAR is cytoplasmic and translocates to the nucleus in response to PB and PB-type inducers such as TCPOBOP and CPZ (13). To examine whether hCAR was also retained in the cytoplasm and translocated into the nucleus after treatment with PB-type inducers, the CFP-tagged hCAR and YFP-tagged hGR were coexpressed in mouse liver in vivo. After injection with the corresponding expression plasmids, frozen sections of the livers were used to visualize these receptors under a fluorescent microscope. The wild-type hCARwt was expressed in the cytoplasm of liver cell, while hGR was primarily localized in the nucleus of the same cell (Fig. 2A), which is opposite from what happened in the transfected HEK293 cells (Fig. 1A). The cytoplasmic and nuclear localization of hCAR and hGR, respectively, appeared to be a true reflection of the nucleocytoplasmic localization supposed to be observed with these receptors in the unexposed livers. To examine whether the cytoplasmic hCARwt could translocate to the nucleus following treatment with PB-type inducers, the mice bearing livers injected with the expression plasmid were treated with CPZ (Fig. 2B). In fact, none of the 70 cells examined exhibited the exclusive nuclear localization of CFP-hCARwt in control livers (Fig. 2C). In sharp contrast to the unexposed liver cells, the majority of the 63 cells examined showed the nuclear localization of the CFP fusion protein in the CPZ-exposed livers. These results thus indicate that the expressed hCARwt is capable of translocating to the nucleus following CPZ treatment in mouse livers.


View larger version (20K):
[in this window]
[in a new window]
  		FIG. 2.   Nucleocytoplasmic distribution of hCAR and its deletions in livers in vivo. (A) YFP-hGR and CFP-hCARwt were coexpressed in the livers of nontreated mice using the in situ DNA injection and then visualized in the same cell under a fluorescence microscope. Panels a and b represent YFP-hGR and CFP-hCARwt, respectively, while panel c shows the stained nuclei. (B) CFP-hCARwt and YFP-hCAR1-338 were coexpressed in the livers of the nontreated and CPZ-treated mice using the in situ DNA injection and then visualized in the same cell under a fluorescence microscope. Panels a and b represent YFP-hCAR1-338 and CFP-hCARwt, respectively, while panel c was stained for nuclei. The three images are imposed in each panel d. (C) The expression plasmids for various hCARs as GFP-tagged protein were directly injected into mouse livers, and the nucleocytoplasmic distribution of the expressed CARs was analyzed in the nontreated (-) and CPZ-treated (+) livers as described in Materials and Methods. The numbers indicate the cell populations as follows: N, nuclear distribution; N/C, distribution in cytoplasm and nucleus; and C, cytoplasmic distribution.

After establishing the in vivo liver system in which the nuclear translocation of hCAR occurred in response to a PB-type inducer, we attempted to define the role of the C-terminal region of hCAR in nuclear translocation. For this, various C-terminal truncated CARs were coexpressed with the wild-type receptor in the same cell. The YFP-tagged hCAR1-338, lacking C-terminal 10 residues (i.e., AF2 domain), was sequestered in the cytoplasm of unexposed livers and translocated to the nucleus following CPZ treatment, which also occurred with the wild-type in same liver cells (Fig. 2B and C). The expressions of CFP-tagged hCARwt and YFP-tagged hCAR1-338 overlapped exactly in the unexposed and CPZ-induced liver cells. In fact, the hCAR1-338 responded not only to CPZ but also to PB and TCPOBOP, indicating that the AF2 domain was nonessential for the nuclear translocation induced by PB-type inducers.

The nuclear translocation of hCAR, however, began to be affected by an additional deletion of the C-terminal residues. When the 20 residues were removed, none of the 32 cells showed the dominant nuclear localization in the CPZ-induced livers (Fig. 2C). However, the hCAR1-328 retained some degree of the nuclear translocation capability in the liver since the receptor was localized equally in the cytoplasm and nucleus of half of these cells. Given the differences in the translocation capability of the truncated receptor in the livers compared with the complete loss in the HEK293 cells, we removed the 30 residues up to position 318 of the hCAR. The YFP-tagged hCAR1-318 was always localized in the cytoplasm even after treatment with CPZ, indicating that the hCAR1-318 lost the nuclear translocation capability in mouse liver (Fig. 3). These results indicated that, first of all, the AF2 domain plays no role in the nuclear translocation in the liver and that the key residue responsible for the hepatic translocation may reside between positions 319 and 328 of the receptor.


View larger version (35K):
[in this window]
[in a new window]
  		FIG. 3.   Nuclear translocation in response to various PB-type iducers. The expression vectors CFP-hCARwt and YFP-hCAR1-318 were simultaneously injected into the livers of mice, and subsequently the mice were treated with PB, CPZ, or TCPOBOP as described in Materials and Methods. For each group, panels a and b display YFP-hCAR1-318 and CFP-hCARwt, respectively; panel c was stained for nuclei; and panel d shows an imposition of all three images.

To search for residue(s) that may regulate the nuclear translocation in the liver, various amino acid residues between positions 319 and 338 were mutated: S321A, I322A, Y326A, Y328A, I330A, I333A, and L336A. These mutations, however, did not affect the nuclear translocation of hCAR (data not shown). Amino acid sequence analysis then revealed a small region of CAR that contains a cluster of Leu residues starting with Leu319 toward the N terminus: L312LGLLAEL319 (Fig. 4). Each of these Leu residues was mutated to Ala, and the mutated YFP-tagged hCARs were coexpressed with the CFP-tagged wild-type receptor in the mouse livers using gene delivery through tail vein injection. Since this delivery system provided us with high transfection efficiency, the expression of a given fluorescent protein-tagged CAR could be observed in multiple cells on same field. The hCAR[L312A] and hCAR[L315A] mutants translocated to the nucleus after CPZ treatment as the wild-type CAR did, whereas the mutants hCAR[L313A], hCAR[L316A], and hCAR[L319A] abrogated the nuclear translocation capability and remained in the cytoplasm even after CPZ treatment (Fig. 5). Thus, the L313XXL316XXL319 appeared to be a motif that regulates the CPZ-inducible nuclear translocation of hCAR in the mouse livers. Retrospectively, the lack of Leu319 was a major reason that hCAR1-318 was unable to translocate to the nucleus in the CPZ-treated livers. Although a role for residues 329 to 338 could not be completely ruled out, any such role might be secondary to the role played by these Leu residues in the nuclear translocation. The L312LGLLAEL319 sequence is conserved in the mouse and rat CARs as L322MGLLADL329 and L322MGLLAEL329, respectively (Leu residues in the motif are underlined). As expected, the mutation of Leu326 or Leu329 to Ala abolished the nuclear translocation of mCAR in the mouse livers (Fig. 6). The C-terminal leucine-rich peptide conserved as L/(M) XXLXXL appeared to be a general response signal that dictates the receptor CAR to translocate to the nucleus following CPZ treatment. We have designated this leucine-rich peptide as the xenochemical response signal (XRS).


View larger version (15K):
[in this window]
[in a new window]
  		FIG. 4.   Alignment of a carboxy-terminal sequence of hCAR with the corresponding region of hGR. The hGR sequence and the localization of the predicted secondary structures are depicted from the Wurtz's multiple alignments (22). The hCAR sequence was then aligned underneath of the sequence of hGR. Residues within the putative LXXLXXL sequence designated the XRS are boxed. The presumed alpha -helices 10, 11, and 12 are indicated by arrows. The numbers indicate the positions of the residues of each receptor. The sizes of DBD and LBD are arbitrary.



View larger version (43K):
[in this window]
[in a new window]
  		FIG. 5.   Nucleocytoplasmic localization of the hCAR mutants. (A) Various mutated hCARs were coexpressed with the wild-type hCAR using the gene delivery system through tail vein injection of their fluorescent protein-tagged expression vectors in the nontreated (-) and CPZ-treated (+) mouse livers as described in Materials and Methods. All three images of YFP-mutated hCAR, CFP-hCARwt, and nuclei stained with Hoechst S-33258 are imposed in these pictures. (B) Semiquantification of the intracellular distribution of various mutated hCAR in liver cells. The numbers indicate the cell populations as follows: N, nuclear distribution; N/C, distribution in cytoplasm and nucleus; and C, cytoplasmic distribution.


View larger version (39K):
[in this window]
[in a new window]
  		FIG. 6.   Nucleocytoplasmic localization of the mCAR mutants. Expression vectors of the wild-type mCAR and of either mCAR mutants were simultaneously injected in mice through the tail vein, and the mice were subsequently treated with CPZ (+CPZ) or dimethyl sulfoxide (-CPZ) as described in Materials and Methods. For each group, panels a and b display the mutated YFP-mCAR and wild-type CFP-mCAR, respectively; panel c was stained for nuclei; and panel d shows an imposition of all three images.

The XRS region overlaps with the region that could be involved in various protein-protein interactions of nuclear receptors. The recent crystal structures of RXR-PPAR and RXR-RAR heterodimers revealed that N-terminal region of helix 10 is located on the dimerization interface of these nuclear receptors (3, 7). Site-directed mutagenesis of residue in the same N-terminal region resulted in the inhibition of receptor heterodimerization (1). Therefore, we examined what degree the Leu mutations of XRS could affect the heterodimerization of hCAR with hRXRalpha . For this, gel shift assays were performed using 32P-labeled NR1 oligonucleotide as a probe (Fig. 7A). Although mutations of each of these Leu residues slightly decreased the band intensities representing the CAR-RXRalpha heterodimer, there was no significant difference in the ability of various mutated hCARs to form RXRalpha heterodimer, regardless of their specific effects on the nuclear translocation of hCAR in mouse livers. We also examined whether the mutations altered the coactivation of hCAR by SRC-1 in HEK293 cells (Fig. 7B). However, the coexpression of SRC-1 resulted in an increase of ca. 70% of all hCAR-mediated transactivations of PBREM in the cotransfected cells. Our present experiments do not suggest that the region of XRS is not involved in various heterodimerizations, but they clearly show that both the RXRalpha heterodimerization and the SRC-1 coactivation are not affected by the Leu mutations that inhibited the nuclear translocation of hCAR. These results suggest that the Leu residues regulate the translocation but not activation of the receptor. Whether the XRS region constitutes and acts as a sequence motif remains an interesting question for future investigation.


View larger version (32K):
[in this window]
[in a new window]
  		FIG. 7.   Effect of Leu mutations on the heterodimerization with RXRalpha and the coactivation by SRC-1. (A) Various mutated hCARs were prepared by in vitro translation and mixed with the similarly prepared RXRalpha for gel shift assays using 32P-labeled NR1 oligonucleotide as a probe. (B) pcDNA3.1 plasmids bearing various hCARs were cotransfected with a PBREM-tk-luciferase reporter plasmid (in pGL3) into HEK293 cells. After being cultured with or without the additional transfection of mSRC-1 for 24 h, the cells were lysed for luciferase activity. The activities were normalized against those of pRL-CMV, and coactivation was calculated as the percentage of the increase by coexpression of SRC-1.

XRS resides on alpha -helix 10 near the C terminus of the CAR molecule, as predicted from the alignment of multiple nuclear receptor sequences (25). The C-terminal alpha -helix 12 bears the AF2 domain; ligand-dependent functions are generally associated with the AF2 domain of nuclear receptors (5, 8). Recent X-ray crystal structures have revealed that alpha -helix 12 is displaced upon binding of the ligand, allowing its association with a coactivator (15, 22). In addition, AF2 has also regulated the ligand-dependent nuclear translocation of vitamin D receptor, in which deletion of the AF2 domain (AF-2del-VDR-GFP) abolished the translocation to the nucleus in response to the vitamin (18). In the case of CAR, however, our present studies have clearly shown that the receptor does not require the AF2 for the PB-induced nuclear translocation in liver in vivo. It is known that the removal of residues within the AF2 domain abrogated the constitutive transactivation activity of hCAR (4). Thus, the nuclear translocation and transactivation appear to be regulated by the different mechanism, and only the latter function is linked to the AF2 domain observed. Instead, the nuclear translocation function resides in the C-terminal LXXLXXL sequence, XRS.

Nuclear localization of a given protein is determined by a balance of nuclear import and export (11, 17), which can be actively regulated by peptide sequences such as the nuclear localization signal (NLS) and the nuclear export signal (NES) built into the protein. XRS does not resemble its sequence with so-called monopartite or bipartite NLSs consisting of a single or repeated cluster of basic amino acids. The NLS associates with specific factors such as importins that carry NLS-bearing proteins into nucleus. Based on its sequence, XRS is not a typical NLS, although the possibility of XRS being a novel NLS still remains an interesting question for future research. The sequence of XRS is somewhat similar to those of the NESs, occurring in the Ah receptor, heat-stable inhibitor of cyclic AMP-dependent protein kinase and human immunodeficiency virus type 1 Rev (6, 12, 24). The XRS acting as an NES may be an alternative possibility: in the liver treated with PB-type inducers, the XRS activity as NES is masked by the heterodimerization with RXR, for example, resulting in the accumulation of CAR in the nucleus. This is a less likely possibility since the CAR without XRS is retained in cytoplasm and is not accumulated in the nucleus of both livers as well as HEK293 cells. Moreover, the Leu mutations of XRS did not abolish the heterodimerization of hCAR with RXRalpha . Thus, the XRS as an NLS is still an interesting possibility.

The molecular and cellular mechanism of how XRS regulates the nuclear translocation of CAR in response to PB-type inducers remains a major interest in future research. Is direct PB binding to CAR essential for the receptor's nuclear translocation? The most potent PB-type inducer TCPOBOP induces the Cyp2b10 gene at a concentration of 10 to 50 nM in mouse primary hepatocytes compared with other PB-type inducers that require micromolar to millimolar concentrations to induce the gene, making it the best candidate for demonstrating its binding. Using sensitive but indirect in vitro binding assays, it has recently been shown that TCPOBOP can bind to mCAR but not to hCAR (14, 23). PB did not exhibit a meaningful binding to either mCAR or hCAR. Under the present circumstances, in which the direct binding is not firmly established, it is difficult to speculate how PB-type inducers activate XRS and translocate the receptor into the nucleus. Our finding of the translocation of hCAR as well as mCAR in the mouse livers following treatment with TCPOBOP, however, is insightful. CAR may translocate to the nucleus in the absence of the direct binding of TCPOBOP to the receptor. The protein phosphatase inhibitor okadaic acid is known to suppress the PB-induced nuclear translocation of mCAR in mouse primary hepatocytes (13). PB-type inducers may elicit a phosphorylation/dephosphorylation pathway that regulates the nuclear translocation of CAR in mouse livers. Although the direct binding mechanism should be considered, the indirect regulation via a protein dephosphorylation offers an alternative direction for future research.

Steroid hormone receptors are sequestered in the cytoplasm; as a multimeric complex with the hsp90 chaperonic system, a detailed hypothesis of the hormone-dependent release of the receptors has been proposed (2). GR is retained in the cytoplasm of transfected HEK293 cells prior to dexamethasone treatment. However, hCAR could not be retained in the cytoplasm and accumulated in the nucleus of the cells. The ability of HEK293 cells to retain GR but not hCAR in the cytoplasm leads us to think that these two receptors are regulated distinctly with respect to their translocation. In fact, the CAR also appeared to exist in the complex with hsp90 in liver cytoplasm (K. Yoshinari et al., unpublished observation), suggesting the presence of factors specific to CAR that regulate the receptor translocation. Since the alpha -helix 10 contains multiple sequences responsible for intramolecular and intermolecular interactions of the nuclear receptors (15), XRS may be one of these sequences and may bind to the specific factors regulating the PB-induced nuclear translocation of CAR in liver in vivo. Identifications of the intramolecular interaction with XRS and of proteins that associate with XRS would help us to uncover the mechanism by which XRS regulates the receptor CAR for the nuclear translocation. To this end, the purification and characterization of CAR as a large complex from the liver cytosol of untreated mice is now under way in this laboratory. Nevertheless, further characterization of XRS should provide insight into the nuclear translocation of CAR and the induction of various genes following exposure to PB-type inducers.


    ACKNOWLEDGMENTS

I.Z. and T.S. contributed equally to this work.


    FOOTNOTES

* Corresponding author. Mailing address: Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709. Phone: (919) 541-2404. Fax: (919) 541-0696. E-mail: negishi{at}niehs.nih.gov.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

1. Au-Fliegner, M., E. Helmer, J. Casanova, B. M. Raaka, and H. H. Samuels. 1993. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediate diverse responses by affecting heterodimer but not homodimer formation. Mol. Cell. Biol. 13:5725-5737[Abstract/Free Full Text].
2. Buchner, J. 1999. Hsp90 & Co.---a holding for folding. Trends Biochem. Sci. 24:136-141[CrossRef][Medline].
3. Bourguet, W., V. Vivat, J.-M. Wurtz, P. Chambon, H. Gronemeyer, and D. Moras. 2000. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 5:289-298[CrossRef][Medline].
4. Choi, H. S., M. Chung, I. Tzameli, D. Simha, Y. K. Lee, W. Seol, and D. D. Moore. 1997. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J. Biol. Chem. 272:23565-23571[Abstract/Free Full Text].
5. Danielian, P. S., R. White, J. A. Lees, and M. G. Parker. 1992. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 11:1025-1033[Medline]. (Erratum, 11: 1015-1023.)
6. Fischer, U., J. Huber, W. C. Boelens, I. W. Mattaj, and R. Luhrmann. 1995. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82:475-483[CrossRef][Medline].
7. Gampe, R. T., V. G. Montana, M. H. Lambert, A. B. Miller, R. K. Bledsoe, M. V. Milburn, S. A. Kliewer, T. M. Willson, and H. E. Xu. 2000. Asymmetry in the PPARgamma /RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 5:545-555[CrossRef][Medline].
8. Glass, C. K., D. W. Rose, and M. G. Rosenfeld. 1997. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9:222-232[CrossRef][Medline].
9. Honkakoski, P., R. Moore, K. A. Washburn, and M. Negishi. 1998. Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol. Pharmacol. 53:597-601[Abstract/Free Full Text].
10. Honkakoski, P., I. Zelko, T. Sueyoshi, and M. Negishi. 1998. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol. Cell. Biol. 18:5652-5658[Abstract/Free Full Text].
11. Hood, J. K., and P. A. Silver. 1999. In or out? Regulating nuclear transport. Curr. Opin. Cell Biol. 11:241-247[CrossRef][Medline].
12. Ikuta, T., H. Eguchi, T. Tachibana, Y. Yoneda, and K. Kawajiri. 1998. Nuclear localization and export signals of the human aryl hydrocarbon receptor. J. Biol. Chem. 273:2895-2904[Abstract/Free Full Text].
13. Kawamoto, T., T. Sueyoshi, I. Zelko, R. Moore, K. Washburn, and M. Negishi. 1999. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol. Cell. Biol. 19:6318-6322[Abstract/Free Full Text].
14. Moore, L. B., D. J. Parks, S. A. Jones, R. K. Bledsoe, T. G. Consler, J. B. Stimmel, B. Goodwin, C. Liddle, S. G. Blanchard, T. M. Willson, J. L. Collins, and S. A. Kliewer. 2000. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275:15122-15127[Abstract/Free Full Text].
15. Nolte, R. T., G. B. Wisely, S. Westin, J. E. Cobb, M. H. Lambert, R. Kurokawa, M. G. Rosenfeld, T. M. Willson, C. K. Glass, and M. V. Milburn. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143[CrossRef][Medline].
16. Park, Y., H. Li, and B. Kemper. 1996. Phenobarbital induction mediated by a distal CYP2B2 sequence in rat liver transiently transfected in situ. J. Biol. Chem. 271:23725-23728[Abstract/Free Full Text].
17. Pennisi, E. 1998. The nucleus's revolving door. Science 279:1129-1131[Free Full Text].
18. Racz, A., and J. Barsony. 1999. Hormone-dependent translocation of vitamin D receptors is linked to transactivation. J. Biol. Chem. 274:19352-19360[Abstract/Free Full Text].
19. Ramsden, R., N. B. Beck, K. M. Sommer, and C. J. Omiecinski. 1999. Phenobarbital responsiveness conferred by the 5'-flanking region of the rat CYP2B2 gene in transgenic mice. Gene 228:169-179[CrossRef][Medline].
20. Stoltz, C., M. H. Vachon, E. Trottier, S. Dubois, Y. Paquet, and A. Anderson. 1998. The CYP2B2 phenobarbital response unit contains an accessory factor element and a putative glucocorticoid response element essential for conferring maximal phenobarbital responsiveness. J. Biol. Chem. 273:8528-8536[Abstract/Free Full Text].
21. Sueyoshi, T., T. Kawamoto, I. Zelko, P. Honkakoski, and M. Negishi. 1999. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem. 274:6043-6046[Abstract/Free Full Text].
22. Tanenbaum, D. M., Y. Wang, S. P. Williams, and P. B. Sigler. 1998. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. USA 95:5998-6003[Abstract/Free Full Text].
23. Tzameli, I., P. Pissios, E. G. Schuetz, and D. Moore. 2000. The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for nuclear receptor CAR. Mol. Cell. Biol. 20:2951-2958[Abstract/Free Full Text].
24. Wen, W., J. L. Meinkoth, R. Y. Tsien, and S. S. Taylor. 1995. Identification of a signal for rapid export of proteins from the nucleus. Cell 82:463-473[CrossRef][Medline].
25. Wurtz, J. M., W. Bourguet, J. P. Renaud, V. Vivat, P. Chambon, D. Moras, and H. Gronemeyer. 1996. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3:206[CrossRef][Medline].

Molecular and Cellular Biology, April 2001, p. 2838-2846, Vol. 21, No. 8
0270-7306/01/$04.00+0   DOI: 10.1128/MCB.21.8.2838-2846.2001


This article has been cited by other articles:

  • Li, L., Chen, T., Stanton, J. D., Sueyoshi, T., Negishi, M., Wang, H. (2008). The Peripheral Benzodiazepine Receptor Ligand 1-(2-Chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide Is a Novel Antagonist of Human Constitutive Androstane Receptor. Mol. Pharmacol. 74: 443-453 [Abstract] [Full Text]  
  • Sueyoshi, T., Moore, R., Sugatani, J., Matsumura, Y., Negishi, M. (2008). PPP1R16A, The Membrane Subunit of Protein Phosphatase 1{beta}, Signals Nuclear Translocation of the Nuclear Receptor Constitutive Active/Androstane Receptor. Mol. Pharmacol. 73: 1113-1121 [Abstract] [Full Text]  
  • Xia, J., Kemper, B. (2007). Subcellular Trafficking Signals of Constitutive Androstane Receptor: Evidence for a Nuclear Export Signal in the DNA-Binding Domain. Drug Metab. Dispos. 35: 1489-1494 [Abstract] [Full Text]  
  • Woods, C. G., Vanden Heuvel, J. P., Rusyn, I. (2007). Genomic Profiling in Nuclear Receptor-Mediated Toxicity. Toxicol Pathol 35: 474-494 [Abstract] [Full Text]  
  • Koike, C., Moore, R., Negishi, M. (2007). Extracellular Signal-Regulated Kinase Is an Endogenous Signal Retaining the Nuclear Constitutive Active/Androstane Receptor (CAR) in the Cytoplasm of Mouse Primary Hepatocytes. Mol. Pharmacol. 71: 1217-1221 [Abstract] [Full Text]  
  • Auerbach, S. S., DeKeyser, J. G., Stoner, M. A., Omiecinski, C. J. (2007). CAR2 Displays Unique Ligand Binding and RXR{alpha} Heterodimerization Characteristics. Drug Metab. Dispos. 35: 428-439 [Abstract] [Full Text]  
  • Faucette, S. R., Zhang, T.-C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M., Wang, H. (2007). Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers. J. Pharmacol. Exp. Ther. 320: 72-80 [Abstract] [Full Text]  
  • Rencurel, F., Foretz, M., Kaufmann, M. R., Stroka, D., Looser, R., Leclerc, I., da Silva Xavier, G., Rutter, G. A., Viollet, B., Meyer, U. A. (2006). Stimulation of AMP-Activated Protein Kinase Is Essential for the Induction of Drug Metabolizing Enzymes by Phenobarbital in Human and Mouse Liver. Mol. Pharmacol. 70: 1925-1934 [Abstract] [Full Text]  
  • Sakai, H., Iwata, H., Kim, E.-Y., Tsydenova, O., Miyazaki, N., Petrov, E. A., Batoev, V. B., Tanabe, S. (2006). Constitutive Androstane Receptor (CAR) as a Potential Sensing Biomarker of Persistent Organic Pollutants (POPs) in Aquatic Mammal: Molecular Characterization, Expression Level, and Ligand Profiling in Baikal Seal (Pusa sibirica). Toxicol Sci 94: 57-70 [Abstract] [Full Text]  
  • Faucette, S. R., Sueyoshi, T., Smith, C. M., Negishi, M., LeCluyse, E. L., Wang, H. (2006). Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X Receptor. J. Pharmacol. Exp. Ther. 317: 1200-1209 [Abstract] [Full Text]  
  • Hosseinpour, F., Moore, R., Negishi, M., Sueyoshi, T. (2006). Serine 202 Regulates the Nuclear Translocation of Constitutive Active/Androstane Receptor. Mol. Pharmacol. 69: 1095-1102 [Abstract] [Full Text]  
  • Johnson, D. R., Li, C.-W., Chen, L.-Y., Ghosh, J. C., Chen, J. D. (2006). Regulation and Binding of Pregnane X Receptor by Nuclear Receptor Corepressor Silencing Mediator of Retinoid and Thyroid Hormone Receptors (SMRT). Mol. Pharmacol. 69: 99-108 [Abstract] [Full Text]  
  • Huang, W., Zhang, J., Washington, M., Liu, J., Parant, J. M., Lozano, G., Moore, D. D. (2005). Xenobiotic Stress Induces Hepatomegaly and Liver Tumors via the Nuclear Receptor Constitutive Androstane Receptor. Mol. Endocrinol. 19: 1646-1653 [Abstract] [Full Text]  
  • Xia, J., Kemper, B. (2005). Structural Determinants of Constitutive Androstane Receptor Required for Its Glucocorticoid Receptor Interacting Protein-1-mediated Nuclear Accumulation. J. Biol. Chem. 280: 7285-7293 [Abstract] [Full Text]  
  • Squires, E. J., Sueyoshi, T., Negishi, M. (2004). Cytoplasmic Localization of Pregnane X Receptor and Ligand-dependent Nuclear Translocation in Mouse Liver. J. Biol. Chem. 279: 49307-49314 [Abstract] [Full Text]  
  • Zhang, J., Huang, W., Qatanani, M., Evans, R. M., Moore, D. D. (2004). The Constitutive Androstane Receptor and Pregnane X Receptor Function Coordinately to Prevent Bile Acid-induced Hepatotoxicity. J. Biol. Chem. 279: 49517-49522 [Abstract] [Full Text]  
  • Wang, H., Faucette, S., Moore, R., Sueyoshi, T., Negishi, M., LeCluyse, E. (2004). Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin. J. Biol. Chem. 279: 29295-29301 [Abstract] [Full Text]  
  • Swales, K., Negishi, M. (2004). CAR, Driving into the Future. Mol. Endocrinol. 18: 1589-1598 [Abstract] [Full Text]  
  • Jinno, H., Tanaka-Kagawa, T., Hanioka, N., Ishida, S., Saeki, M., Soyama, A., Itoda, M., Nishimura, T., Saito, Y., Ozawa, S., Ando, M., Sawada, J.-i. (2004). Identification of Novel Alternative Splice Variants of Human Constitutive Androstane Receptor and Characterization of Their Expression in the Liver. Mol. Pharmacol. 65: 496-502 [Abstract] [Full Text]  
  • Chen, Y., Ferguson, S. S., Negishi, M., Goldstein, J. A. (2004). Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor. J. Pharmacol. Exp. Ther. 308: 495-501 [Abstract] [Full Text]  
  • Handschin, C., Meyer, U. A. (2003). Induction of Drug Metabolism: The Role of Nuclear Receptors. Pharmacol. Rev. 55: 649-673 [Abstract] [Full Text]  
  • Kobayashi, K., Sueyoshi, T., Inoue, K., Moore, R., Negishi, M. (2003). Cytoplasmic Accumulation of the Nuclear Receptor CAR by a Tetratricopeptide Repeat Protein in HepG2 Cells. Mol. Pharmacol. 64: 1069-1075 [Abstract] [Full Text]  
  • Yudt, M. R., Jewell, C. M., Bienstock, R. J., Cidlowski, J. A. (2003). Molecular Origins for the Dominant Negative Function of Human Glucocorticoid Receptor Beta. Mol. Cell. Biol. 23: 4319-4330 [Abstract] [Full Text]  
  • Kawajiri, K., Ikuta, T., Suzuki, T., Kusaka, M., Muramatsu, M., Fujieda, K., Tachibana, M., Morohashi, K.-i. (2003). Role of the LXXLL-Motif and Activation Function 2 Domain in Subcellular Localization of Dax-1 (Dosage-Sensitive Sex Reversal-Adrenal Hypoplasia Congenita Critical Region on the X Chromosome, Gene 1). Mol. Endocrinol. 17: 994-1004 [Abstract] [Full Text]  
  • Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi, M., LeCluyse, E. L. (2003). A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression. J. Biol. Chem. 278: 14146-14152 [Abstract] [Full Text]  
  • Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., Moore, D. D. (2003). Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl. Acad. Sci. USA 100: 4156-4161 [Abstract] [Full Text]  
  • Schaaf, M. J. M., Cidlowski, J. A. (2003). Molecular Determinants of Glucocorticoid Receptor Mobility in Living Cells: the Importance of Ligand Affinity. Mol. Cell. Biol. 23: 1922-1934 [Abstract] [Full Text]  
  • Kawana, K., Ikuta, T., Kobayashi, Y., Gotoh, O., Takeda, K., Kawajiri, K. (2003). Molecular Mechanism of Nuclear Translocation of an Orphan Nuclear Receptor, SXR. Mol. Pharmacol. 63: 524-531 [Abstract] [Full Text]  
  • Zhang, J., Huang, W., Chua, S. S., Wei, P., Moore, D. D. (2002). Modulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR. Science 298: 422-424 [Abstract] [Full Text]  
  • Goodwin, B., Hodgson, E., D'Costa, D. J., Robertson, G. R., Liddle, C. (2002). Transcriptional Regulation of the Human CYP3A4 Gene by the Constitutive Androstane Receptor. Mol. Pharmacol. 62: 359-365 [Abstract] [Full Text]  
  • Min, G., Kemper, J. K., Kemper, B. (2002). Glucocorticoid Receptor-interacting Protein 1 Mediates Ligand-independent Nuclear Translocation and Activation of Constitutive Androstane Receptor in Vivo. J. Biol. Chem. 277: 26356-26363 [Abstract] [Full Text]  
  • Ueda, A., Kakizaki, S., Negishi, M., Sueyoshi, T. (2002). Residue Threonine 350 Confers Steroid Hormone Responsiveness to the Mouse Nuclear Orphan Receptor CAR. Mol. Pharmacol. 61: 1284-1288 [Abstract] [Full Text]  
  • Ueda, A., Hamadeh, H. K., Webb, H. K., Yamamoto, Y., Sueyoshi, T., Afshari, C. A., Lehmann, J. M., Negishi, M. (2002). Diverse Roles of the Nuclear Orphan Receptor CAR in Regulating Hepatic Genes in Response to Phenobarbital. Mol. Pharmacol. 61: 1-6 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zelko, I.
Right arrow Articles by Negishi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zelko, I.
Right arrow Articles by Negishi, M.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»